GI & Endoscopy

AbbVie, Galapagos Partner to Test Possible Chrohn’s Disease Drug

AbbVie, North Chicago, Ill.-based pharmaceutical research and development company, is working with Galapagos, Mechelen, Belgium-based pharmaceutical company, to test if Janus kinase inhibitor can be used as a Chrohn’s disease treatment, according to a Zenopa report.

Carrie Pallardy

Wednesday, May 22nd, 2013

Galapagos will begin a phase II trial of the drug with 180 patients in 2014. The companies hope the drug will quickly move to a phase III trial.

More Articles on Gastroenterology:
8 Trends Shaping the Present & Future of Gastroenterology
Dr. Andrew Rhim Receives AGA Digestive Cancer Award, $40k Grant
Boston Scientific to Present Data at Digestive Disease Week

Next Up in GI & Endoscopy

FDA clears final trial stage for robotic GI surgery system

EndoQuest Robotics has received FDA approval to proceed with the final enrollment phase of its pivotal Paradigm trial evaluating a…

By: Sophie Eydis
2 days ago
Gastroenterologist pay breakdown in 10 stats

As of Dec. 14, gastroenterologists’ average annual salary is $583,380, according to salary transparency platform Marit Health’s compilation of 215…

By: Patsy Newitt
2 days ago
5 GI leaders on what’s changing in colonoscopy

Colonoscopy remains a cornerstone of colorectal cancer prevention, but GI leaders say the procedure’s role, and the business model built…

By: Patsy Newitt
2 days ago

Comments are closed.

The implementation gap: Bridging AI promises and healthcare realities

Next Up in GI & Endoscopy

FDA clears final trial stage for robotic GI surgery system

Gastroenterologist pay breakdown in 10 stats

5 GI leaders on what’s changing in colonoscopy

Join the 40,000+ ASC leaders who start their day with Becker's